{Reference Type}: Journal Article
{Title}: UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high-dose chemoradiotherapy for patients with malignancy.
{Author}: Douglas KW;Gilleece M;Hayden P;Hunter H;Johnson PRE;Kallmeyer C;Malladi RK;Paneesha S;Pawson R;Quinn M;Raj K;Richardson D;Robinson S;Russell N;Snowden J;Sureda A;Tholouli E;Thomson K;Watts M;Wilson KM;
{Journal}: J Clin Apher
{Volume}: 33
{Issue}: 1
{Year}: Feb 2018
{Factor}: 2.605
{DOI}: 10.1002/jca.21563
{Abstract}: Plerixafor is a CXC chemokine receptor (CXCR4) antagonist that mobilizes stem cells in the peripheral blood. It is indicated (in combination with granulocyte-colony stimulating factor [G-CSF]) to enhance the harvest of adequate quantities of cluster differentiation (CD) 34+ cells for autologous transplantation in patients with lymphoma or multiple myeloma whose cells mobilize poorly. Strategies for use include delayed re-mobilization after a failed mobilization attempt with G-CSF, and rescue or pre-emptive mobilization in patients in whom mobilization with G-CSF is likely to fail. Pre-emptive use has the advantage that it avoids the need to re-schedule the transplant procedure, with its attendant inconvenience, quality-of-life issues for the patient and cost of additional admissions to the transplant unit. UK experience from 2 major centers suggests that pre-emptive plerixafor is associated with an incremental drug cost of less than £2000 when averaged over all patients undergoing peripheral blood stem cell (PBSC) transplant. A CD34+ cell count of <15 µl-1 at the time of recovery after chemomobilization or after four days of G-CSF treatment, or an apheresis yield of <1 × 106 CD34+ cells/kg on the first day of apheresis, could be used to predict the need for pre-emptive plerixafor.